Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
6,144
datasets available to search
ShareScore release 0.9.0
Dataset results
6,144 results for “cancer treatment”
Pegylated Liposomal Doxorubicin and Carboplatin as First Line Treatment for Patients With Advanced Non-small Cell Lung Cancer
ClinicalTrials.gov study NCT01051362. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Ultrasound-assisted Treatment of Inoperable Pancreatic Cancer
ClinicalTrials.gov study NCT01674556. IPD Sharing: Not stated. Countries: 1. Publications: 1.
NGS as the First-line Treatment in Advanced Biliary Tract Cancer
ClinicalTrials.gov study NCT04172402. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
ClinicalTrials.gov study NCT05382299. IPD Sharing: NO. Countries: 30. Publications: 1.
Laparoscopic and Endoscopic Collaborative Surgery as Rescue-treatment for Advanced Gastric Cancer
ClinicalTrials.gov study NCT06105515. IPD Sharing: NO. Countries: 1. Publications: 6.
Cost-effectiveness analysis of cetuximab combined with chemotherapy as a first-line treatment for RAS wild-type metastatic colorectal cancer patients based on the TAILOR trial
Open the record for dataset details and reuse information.
Data from: Outcome of breast cancer in Moroccan young women correlated to clinic-pathological features, risk factors and treatment: a comparative study of 716 cases in a single institution
Open the record for dataset details and reuse information.
Data from: Early treatment response in non-small cell lung cancer patients using diffusion-weighted imaging and functional diffusion maps - a feasibility study
Open the record for dataset details and reuse information.
Data from: A clinical decision support system learned from data to personalize treatment recommendations towards preventing breast cancer metastasis
Open the record for dataset details and reuse information.
Half-Dose Fulvestrant plus Anastrozole as a First-Line Treatment for Hormone Receptor-Positive Metastatic Breast Cancer: A Cost-Effectiveness Analysis
Open the record for dataset details and reuse information.
Metabolomics dataset for identification of metabolites associated with survival in lung cancer patients under treatment
<p>Non small cell lung cancer patients' serum samples were collected before treatment. The samples were analyzed by metabolomics using high resolution NMR and untargeted lipidomics using high resolution UPLC-MS. The data was used to identify the predictors of overall survival in the patients after they underwent treatment.</p>
Indirect comparison between immunotherapy alone and immunotherapy plus chemotherapy as first-line treatment for advanced non-small cell lung cancer: A systematic review
<p><b>Objectives:</b> Use of immune checkpoint inhibitors (ICIs) as first-line treatment for advanced (stage IIIB/IV) non-small cell lung cancer (NSCLC) remains controversial. Clinical trials comparing single-drug immunotherapy (IO) with immunotherapy plus chemotherapy (IC) are lacking. We aimed to compare the efficacy of IO alone with that of IC as first-line treatment for advanced NSCLC.</p> <p><b>Design: </b>Systematic review</p> <p><b>Data sources: </b>PubMed, the Cochrane Library, and Embase for related studies on NSCLC; ClinicalTrials.gov, American Society of Clinical Oncology Meeting Library, and World Conference on Lung Cancer for relevant conference abstracts.</p> <p><b>Eligibility criteria: </b>Articles<b> </b>meeting the following<b> </b>criteria were selected: (1) randomized controlled trials on NSCLC treatment, (2) all individuals in the studies had not received treatment previously, and (3) research on IO monotherapy using programmed death-1/programmed death ligand-1 (PD-L1) inhibitors or IC.</p> <p><b>Data extraction and synthesis:</b> After reading the original literature, two reviewers independently extracted the relevant information. The primary outcomes were progression-free survival (PFS), overall survival (OS), and objective response rate (ORR). We also extracted data on treatment-related adverse events and immune-related adverse events (irAEs).</p> <p><b>Results:</b> Overall, 10 randomized controlled clinical trials (n = 5765) were included. As first-line treatment for advanced NSCLC, IC tended to yield better PFS, OS, and ORR than did IO. Furthermore, IC yielded significantly better PFS than IO when tumor PD-L1 expression was at least 50% (HR: 1.81, 95% CI: 1.18–2.78) and yielded a better OS and PFS when tumor PD-L1 expression was at least 1%; IO resulted in fewer adverse events than did IC. However, the incidence of irAEs was higher for IO than for IC.</p> <p><b>Conclusions:</b> The findings of the indirect comparison indicate that IC as first-line treatment for advanced NSCLC is significantly more effective than IO in patients with PD-L1 expression in at least 50% of tumor cells.</p>
Data from: Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis
Objectives: Bevacizumab and erlotinib inhibit different tumour growth pathways, and both exhibit beneficial effects in the treatment of non-small-cell lung cancer (NSCLC). However, the efficacy of bevacizumab in combination with erlotinib remains controversial. Therefore, we conducted a meta-analysis to compare combination treatment with bevacizumab and erlotinib to bevacizumab or erlotinib monotherapy in the treatment of NSCLC. Methods: Randomised controlled trials (RCTs) published in PubMed, Web of Science and EMBASE were systematically reviewed. The main outcome measures included overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and adverse events. Results were expressed as HRs or risk ratios (RRs) with 95% CIs. Results: 5 RCTs involving a total of 1736 patients were included in this meta-analysis. The combination of bevacizumab and erlotinib significantly improved PFS (HR=0.63, 95% CI 0.53 to 0.75; p=0.000) and the ORR (RR=1.91, 95% CI 1.19 to 3.06; p=0.007) in the second-line treatment of NSCLC compared with bevacizumab or erlotinib alone. However, no significant difference in OS was observed between the combination and monotherapy groups (HR=0.96, 95% CI 0.83 to 1.11; p=0.573). A subgroup analysis has shown that the greatest PFS benefit was associated with an age of <65 years(HR=0.74, 95% CI 0.57 to 0.96; p=0.026), Asian/Pacific Islander ethnicity (HR=0.23, 95% CI 0.10 to 0.54; p=0.001), Eastern Cooperative Oncology Group performance status (ECOG PS) 1 (HR=0.82, 95% CI 0.68 to 0.98; p=0.033), stage IIIB or IV disease (HR=0.68, 95% CI 0.57 to 0.82; p=0.000) and no history of smoking (HR=0.48, 95% CI 0.32 to 0.71; p=0.000). The incidence of grade 3/4 adverse events such as rash and diarrhoea was higher in the combination group than in the monotherapy group. Conclusions: The addition of bevacizumab to erlotinib can significantly improve PFS and the ORR in the second-line treatment of NSCLC with an acceptable and manageable risk of rash and diarrhoea. Further well-conducted, large-scale trials are needed to validate these findings.
Data from: Anthracycline drugs on modified surface of quercetin-loaded polymer nanoparticles: a dual drug delivery model for cancer treatment
Polymer nanoparticles are vehicles used for delivery of hydrophobic anti-cancer drugs, like doxorubicin, paclitaxel or chemopreventors like quercetin (Q). The present study deals with the synthesis and characterisation of nano formulations (NFs) from Q loaded PLGA (poly lactic-co-glycolic acid) nano particles (NPs) by surface modification. The surface of Q-loaded (NPs) is modified by coating with biopolymers like bovine serum albumin (BSA) or histones (His). Conventional chemotherapeutic drugs adriamycin (ADR) and mitoxantrone (MTX) are bound to BSA and His respectively before being coated on Q-loaded NPs to nano formulate NF1 and NF2 respectively. The sizes of these NFs are in the range 400-500 nm as ascertained by SEM and DLS measurements. Encapsulation of Q in polymer NPs is confirmed from shifts in FT-IR, TGA and DSC traces of Q-loaded NPs compared to native PLGA and Q. Surface modification in NFs is evidenced by three distinct regions in their TEM images; the core, polymer capsule and the coated surface. Negative zeta potential of Q-loaded NPs shifted to positive potential on surface modification in NF1 and NF2. In vitro release of Q from the NFs lasted up to twenty days with an early burst release. NF2 is better formulation than NF1 as loading of MTX is 85% compared to 23% loading of ADR. Such NFs are expected to overcome multi-drug resistance (MDR) by reaching and treating the target cancerous cells by virtue of size, charge and retention.
Data - Effectiveness of treatments for oral mucositis in pediatric patients with cancer
Open the record for dataset details and reuse information.
GANDALF: Generative AttentioN based Data Augmentation and predictive modeLing Framework for personalized cancer treatment
Open the record for dataset details and reuse information.
Spatial Transcriptomic Experiment of Triple-Negative Breast Cancer PDX Model PIM001-P model treatment naive sample
<p>Spatial Transcriptomic Experiment of Triple-Negative Breast Cancer PDX Model PIM001-P model treatment naive sample</p> <p>10X Genomics Visium platform. </p> <p><strong>Library Preparation and Sequencing of PIM001P</strong></p> <p>Tissue sections of 10µm thickness were mounted onto the capture areas of the Visium Spatial Gene Expression slide and stained using hematoxylin and eosin. Tissue sections were permeabilized on a thermocycler for 24 minutes, as determined by the Tissue Optimization step. Poly-adenlyated mRNA is released and captured by surface-bound primers within each capture area. Reverse transcription, template switching, extension, and second strand synthesis are performed on the slide. Full-length, spatially barcoded cDNA transcripts are then denatured from the slide and amplified via PCR prior to library construction. Approximately 110 to 375 ng of amplified cDNA was carried forward into library construction. During library construction, cDNA is enzymatically fragmented to target amplicon size then undergoes end repair, A-tailing, adapter ligation, and then amplified using between 14 and 16 PCR cycles. The resulting libraries were quantitated using the Invitrogen Qubit 2.0 quantitation assay and fragment size assessed with the Agilent Bioanalyzer. A qPCR quantitation was performed on the libraries to determine the concentration of adapter ligated fragments using Applied Biosystems ViiA7 Real-Time PCR System and a KAPA Library Quant Kit (p/n KK4824). All samples were pooled equimolarly and re-quantitated by qPCR, and also re-assessed on the Bioanalyzer.</p> <p><strong>Sequencing: </strong></p> <p>150 pM of equimolarly pooled library was loaded onto the NovaSeq 6000 S4 flowcell and sequenced at the recommended 28-10-10-50 read configuration. PhiX Control v3 adapter-ligated library (Illumina p/n FC-110-3001) was spiked-in at 2% by weight to ensure balanced diversity and to monitor clustering and sequencing performance. A minimum of 300 million read pairs per sample was sequenced. FastQ file generation was executed using 10X Genomics’ Space Ranger mkfastq software.</p> <p> </p>
Deuterium Magnetic Resonance Imaging Using Deuterated Water-Induced 2H-Tissue Labeling Allows Monitoring Cancer Treatment at Clinical Field Strength
<p>Raw 2H-NMR Data of deuterium content in tumor tissues. </p>
Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials
ClinicalTrials.gov study NCT03477175. IPD Sharing: Not stated. Countries: 11. Publications: 0.
Pembrolizumab With Locally Delivered Radiation Therapy for the Treatment of Metastatic Esophageal Cancers
ClinicalTrials.gov study NCT02642809. IPD Sharing: NO. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.